Free Trial

Arbutus Biopharma (ABUS) Stock Forecast & Price Target

0.00 (0.00%)
(As of 07/19/2024 ET)

Arbutus Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 3 Wall Street analysts who have issued ratings for Arbutus Biopharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for ABUS.

Consensus Price Target

17.43% Upside
High Forecast$5.00
Average Forecast$4.33
Low Forecast$4.00

According to the 3 analysts' twelve-month price targets for Arbutus Biopharma, the average price target is $4.33. The highest price target for ABUS is $5.00, while the lowest price target for ABUS is $4.00. The average price target represents a forecasted upside of 17.43% from the current price of $3.69.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.33$4.33$4.33$6.00
Forecasted Upside17.43% Upside27.70% Upside52.58% Upside102.25% Upside
Get Arbutus Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

ABUS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABUS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arbutus Biopharma Stock vs. The Competition

TypeArbutus BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside17.43% Upside3,282.89% Upside10.04% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/6/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00+37.74%
6/5/2024Chardan Capital
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00+10.19%
4/4/2024JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Outperform$4.00+36.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:39 AM ET.

ABUS Forecast - Frequently Asked Questions

What is Arbutus Biopharma's forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Arbutus Biopharma is $4.33, with a high forecast of $5.00 and a low forecast of $4.00.

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.

Does Arbutus Biopharma's stock price have much upside?

According to analysts, Arbutus Biopharma's stock has a predicted upside of 27.70% based on their 12-month stock forecasts.

What analysts cover Arbutus Biopharma?

Arbutus Biopharma has been rated by research analysts at Chardan Capital, and HC Wainwright in the past 90 days.

Do Wall Street analysts like Arbutus Biopharma more than its competitors?

Analysts like Arbutus Biopharma more than other "medical" companies. The consensus rating for Arbutus Biopharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ABUS compares to other companies.

This page (NASDAQ:ABUS) was last updated on 7/21/2024 by Staff

From Our Partners